Bayer | Pharmaceuticals

💰The global cost of stroke exceeds $891 billion, placing a significant burden on patients and healthcare systems. 🧠 Stroke recovery should not be limited by financial constraints – improving access to post-stroke care is essential. 💬 “We would like to help other people who don’t have the opportunity to recover because they don’t have the money." – Javier, Stroke Survivor 🔎 Watch Javier’s story and why access to stroke care matters. For more information on stroke, visit: http://spr.ly/60484K39E #TheInvisibleMadeVisible #StrokeActionNow #NoToTwo *Feigin VL, et al. Int J Stroke. 2022;17:16–29.

Our own Global Medical Affairs and Evidence Generation Lead, Dr. Cecilia Caetano, has penned an insightful article about the significant impact menopause has on women's lives. Despite the challenges, many women have chosen to remain silent about their struggles and cope with debilitating symptoms alone. Drawing from her clinical experience, she has highlighted 10 key insights to help both professionals and society gain a deeper understanding of menopause. Here are three key takeaways: 🌍 Every menopause is different: While every woman experiences menopause, each journey is distinctly different. 💼 Professional implications for women: In the UK, around 70% of women reported negative impact of menopause symptoms at work, with 17% considering leaving their jobs due to inadequate support for menopause. 🧠 Mental health matters too: Up to 50% of women experience anxiety and depression during perimenopause and menopause. Check out the full article for more insights! 👉 http://spr.ly/6045fBui9

The Supervisory Board of Bayer has today extended my contract. I’m humbled by their trust! This is also a vote of confidence in the work that the 90,000 people of #TeamBayer are doing to advance the mission of the company on behalf of farmers, patients, and consumers.   Here’s what we’re focused on right now: - Delivering our financial commitments in a crucial year for the company and making progress on litigation - Advancing our pipeline for the future with new therapies for heart health, Parkinson’s, higher-yielding and more robust corn and soybean seeds, novel consumer health tools, and more! - Making Bayer the leanest, fastest, most innovative life-science company through our bold operating system    In all things, we continue in service of our mission: Health for all, Hunger for none! https://lnkd.in/dzVrvtAw

Why is menopause still considered taboo when it’s a natural transition every woman experiences? Talking about menopause openly in everyday life and at work helps create understanding. Only then can we ensure women’s experiences are better acknowledged and their needs fully addressed. #TeamBayer is committed to fostering greater understanding and empowering women seeking menopause care. #HealthForAll #HungerForNone

+++#NEWS+++ The U.S. FDA has approved a new therapy for adult patients living with a common form of heart failure. Patients living with heart failure with a left ventricular ejection fraction (LVEF) of ≥40%, also known as heart failure with mildly reduced or preserved ejection fraction, have a substantial risk for cardiovascular events, posing a significant challenge to many physicians. Heart Failure is a key focus area for us, and #TeamBayer remains committed to advancing new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. Learn more: http://spr.ly/60474NuAL

In line with our commitment to supporting patients with wet age-related #MacularDegeneration, Nicholas shares a crucial piece of advice: stick to your treatment schedule! In addition to this, early detection and timely treatment are vital for maintaining quality of life. #TeamBayer continues to raise awareness about eye health and the importance of consistent care.

+++#NEWS+++ #BayerInRadiology is proud to announce the submission of a marketing authorization application in the EU for a new low dose MRI contrast agent. Find out more: http://spr.ly/60494t7Iv

Recientemente se conoció que Bayer fue reconocido en Investigación Clínica como el patrocinador #1 en la industria farmacéutica. ¡Y desde LATAM estamos muy orgullosos de poder decir que somos la segunda región con mejor desempeño en el mundo! 📍Según la Encuesta CenterWatch 2025, LATAM está solo detrás de Europa del Este. 🥇Ser Top Sponsor significa que nuestros clientes y centros de investigación recomiendan activamente trabajar con nosotros. Más de 12 mil centros de investigación de todo el mundo participaron de la Encuesta Global de Relaciones con Sitios de CenterWatch 2025. El 11% de ellos son de LATAM. Esto es fruto de nuestro enorme compromiso, que se ve en el apoyo excepcional en proyectos, relaciones profesionales de monitoreo y estilos de trabajo colaborativos. 🤝🏼 ¿Por qué es importante? De este arduo trabajo surgen las investigaciones que dan como resultado mejoras en medicamentos e importantes avances en la lucha contra las enfermedades. Es parte fundamental de nuestra visión. Y de ofrecer esperanza a miles de pacientes.   #TeamBayer #WCGCenterWatch

💡 Many stroke survivors live with the fear of recurrence. 💬 “I was petrified of having a second stroke. And I haven't yet met a stroke survivor who doesn't feel the same way” – Sas, Stroke Survivor 🔎See what’s often missed. Watch Sas’s story now and help make the invisible visible. Learn more at: http://spr.ly/60484K39E #TheInvisibleMadeVisible #NoToTwo #StrokeActionNow *Dawson J, et al. Eur Stroke J. 2022;7:I–XLI. *Kleindorfer DO, et al. Stroke. 2021;52(7):e364–e467. *Greco A, et al. J Am Coll Cardiol. 2023;82(15):1538–1557. *Johnston SC, et al. N Engl J Med. 2018;379:215–225.

+++#NEWS+++ #TeamBayer, together with BlueRock Therapeutics, shares that the first patient has been enrolled in a Phase 1/2a clinical trial of an investigational cell therapy targeting primary photoreceptor diseases. With this therapy, we aim to restore vision for individuals affected by inherited retinal disorders, offering hope to patients and caregivers facing the challenges of irreversible vision loss. Learn more: http://spr.ly/60494SwWv